Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: Ann Rheum Dis. 2015 Feb 5;75(3):617–622. doi: 10.1136/annrheumdis-2014-206297

Figure 1. SG dysfunction is most prominent in Ro52 immunized mice and it correlates with levels of anti-Ro52 antibody.

Figure 1

A. Immunoprecipitating anti-mRo52 antibodies are generated in 7 out of 8 NZM2758 mice immunized with Ro52. Data is represented as ΔCPM, which is CPM with serum sample minus CPM without serum. None of the MBP immunized mice have antibodies over the cutoff, which is mean ΔCPM+2SD for MBP immunized mice. Mann-Whitney test was used to determine the statistical significance. B. In comparison with untreated mice, Ro52 immunized mice show a 65% drop and MBP immunized mice show a 28% drop in mean saliva volumes. Kruskal–Wallis test was used to determine the statistical significance and ****indicates p<0.0001. The number of mice used provides the experiment >99% power at a significance level (alpha) of 0.05 (two-tailed) C. Inverse correlation is seen between saliva volume and level of anti-Ro52 antibody (p=0.0016; r = −0.802) as determined by Spearman correlation test.